

EN



COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels, 04/06/2003  
C(2003) 1843

NOT FOR PUBLICATION

**COMMISSION DECISION**

**of 04/06/2003**

**amending Decision C(2001)818 on the marketing authorization for  
the medicinal product for human use**

**"TARGRETIN - bexarotene"**

**(Text with EEA relevance)**

ONLY THE ENGLISH TEXT IS AUTHENTIC.

# **COMMISSION DECISION**

**of 04/06/2003**

**amending Decision C(2001)818 on the marketing authorization for  
the medicinal product for human use**

**"TARGRETIN - bexarotene"**

**(Text with EEA relevance)**

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products<sup>1</sup>, as amended by Commission Regulation (EC) No 649/98<sup>2</sup>, and in particular Article 10(2) thereof,

Having regard to the opinion of the European Agency for the Evaluation of Medicinal Products,

Whereas:

- (1) The medicinal product "TARGRETIN - bexarotene" entered in the Community register of medicinal products under Nos EU/1/01/178/001 authorised by Commission Decision C(2001)818 of 29 March 2001, as amended, complies with the requirements set out in Regulation (EEC) No 2309/93.
- (2) Ligand Pharmaceuticals UK Ltd submitted an application to change the package leaflet on 23 April 2003 pursuant to Article 61(3) of Directive 2001/83/EC<sup>3</sup>.
- (3) The proposed changes are not connected with the contents of the summary of characteristics of the medicinal product in question.
- (4) The package leaflet as changed continues to comply with Title V of Directive 2001/83/EC
- (5) Decision C(2001)818 should therefore be amended accordingly.

---

<sup>1</sup> OJ No L 214, 24. 8. 1993, p. 1.

<sup>2</sup> OJ L 88, 24.3.1998, p. 7.

<sup>3</sup> OJ L 311, 28.11.2001, p. 67.

HAS ADOPTED THIS DECISION:

*Article 1*

Decision C(2001)818 is amended as follows:

a) Annex III B is replaced by the Annex to this Decision.

*Article 2*

This Decision is addressed to Ligand Pharmaceuticals UK Ltd, Innovis House, 108 High Street, Crawley, West Sussex RH10 1BB, UNITED KINGDOM.

Done at Brussels, 04/06/2003

*For the Commission*

*Erkki LIIKANEN*

*Member of the Commission*